Published in Nat Rev Clin Oncol on August 09, 2011
Study of Immunotherapy to Treat Advanced Prostate Cancer | NCT00861614
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer | NCT01057810
Neoadjuvant Ipilimumab in Prostate Cancer | NCT01194271
Ipilimumab and Sargramostim in Treating Patients With Metastatic Prostate Cancer | NCT00064129
MDX-010 for Advanced Prostate Cancer | NCT00170157
Vaccine Therapy in Treating Patients With Stage D0 Prostate Cancer | NCT00514072
Large oncosomes in human prostate cancer tissues and in the circulation of mice with metastatic disease. Am J Pathol (2012) 1.60
β-catenin is required for prostate development and cooperates with Pten loss to drive invasive carcinoma. PLoS Genet (2013) 1.24
The RNA-binding protein HuR opposes the repression of ERBB-2 gene expression by microRNA miR-331-3p in prostate cancer cells. J Biol Chem (2011) 1.20
Androgen receptor serine 81 phosphorylation mediates chromatin binding and transcriptional activation. J Biol Chem (2012) 1.13
Evolution of androgen receptor targeted therapy for advanced prostate cancer. Nat Rev Clin Oncol (2014) 1.08
Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression. Int J Oncol (2012) 1.02
Targeting GRPR in urological cancers--from basic research to clinical application. Nat Rev Urol (2013) 1.01
Identification of novel androgen-regulated pathways and mRNA isoforms through genome-wide exon-specific profiling of the LNCaP transcriptome. PLoS One (2011) 1.00
Sprouty2, PTEN, and PP2A interact to regulate prostate cancer progression. J Clin Invest (2013) 0.99
HES6 drives a critical AR transcriptional programme to induce castration-resistant prostate cancer through activation of an E2F1-mediated cell cycle network. EMBO Mol Med (2014) 0.98
Prostate cancer - a biomarker perspective. Front Endocrinol (Lausanne) (2012) 0.97
The developing story of Sprouty and cancer. Cancer Metastasis Rev (2014) 0.96
Response of the insulin-like growth factor (IGF) system to IGF-IR inhibition and androgen deprivation in a neoadjuvant prostate cancer trial: effects of obesity and androgen deprivation. J Clin Endocrinol Metab (2013) 0.93
Advanced prostate cancer--a case for adjuvant differentiation therapy. Nat Rev Urol (2012) 0.93
Future perspectives of prostate cancer therapy. Transl Androl Urol (2012) 0.91
The stroma-a key regulator in prostate function and malignancy. Cancers (Basel) (2012) 0.88
Targeting Androgen Receptor Activation Function-1 with EPI to Overcome Resistance Mechanisms in Castration-Resistant Prostate Cancer. Clin Cancer Res (2016) 0.87
Sequence of treatment in locally advanced and metastatic renal cell carcinoma. Transl Androl Urol (2015) 0.86
Subverting ER-stress towards apoptosis by nelfinavir and curcumin coexposure augments docetaxel efficacy in castration resistant prostate cancer cells. PLoS One (2014) 0.86
Intravenous therapies for castration-resistant prostate cancer: toxicities and adverse events. Urol Oncol (2011) 0.85
Elevated LIM kinase 1 in nonmetastatic prostate cancer reflects its role in facilitating androgen receptor nuclear translocation. Mol Cancer Ther (2014) 0.85
Silibinin derivatives as anti-prostate cancer agents: Synthesis and cell-based evaluations. Eur J Med Chem (2015) 0.84
Acid ceramidase as a therapeutic target in metastatic prostate cancer. J Lipid Res (2013) 0.84
Pharmacologic suppression of JAK1/2 by JAK1/2 inhibitor AZD1480 potently inhibits IL-6-induced experimental prostate cancer metastases formation. Mol Cancer Ther (2014) 0.84
Predictive value of Sp1/Sp3/FLIP signature for prostate cancer recurrence. PLoS One (2012) 0.83
Targeted α-particle therapy of bone metastases in prostate cancer. Clin Nucl Med (2013) 0.82
Personalization of prostate cancer prevention and therapy: are clinically qualified biomarkers in the horizon? EPMA J (2012) 0.81
STAMP2 increases oxidative stress and is critical for prostate cancer. EMBO Mol Med (2015) 0.81
ELF3 is a repressor of androgen receptor action in prostate cancer cells. Oncogene (2013) 0.81
Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study. J Immunother Cancer (2015) 0.81
Evidence of mTOR Activation by an AKT-Independent Mechanism Provides Support for the Combined Treatment of PTEN-Deficient Prostate Tumors with mTOR and AKT Inhibitors. Transl Oncol (2012) 0.81
Targeting and killing of metastatic cells in the transgenic adenocarcinoma of mouse prostate model with vesicular stomatitis virus. Mol Ther (2013) 0.81
Reappraisal of glucocorticoids in castrate-resistant prostate cancer. Asian J Androl (2014) 0.81
Mechanistic Insights into Molecular Targeting and Combined Modality Therapy for Aggressive, Localized Prostate Cancer. Front Oncol (2016) 0.79
Prostate cancer stem cells: The case for model systems. J Carcinog (2012) 0.79
Inhibition of Stat5a/b Enhances Proteasomal Degradation of Androgen Receptor Liganded by Antiandrogens in Prostate Cancer. Mol Cancer Ther (2014) 0.79
Androgen receptors beyond prostate cancer: an old marker as a new target. Oncotarget (2015) 0.78
Oncolytic vaccinia virus as a vector for therapeutic sodium iodide symporter gene therapy in prostate cancer. Gene Ther (2016) 0.78
Drug discovery in advanced prostate cancer: translating biology into therapy. Nat Rev Drug Discov (2016) 0.78
Evaluation of vesicular stomatitis virus mutant as an oncolytic agent against prostate cancer. Int J Clin Exp Med (2014) 0.78
High-content positional biosensor screening assay for compounds to prevent or disrupt androgen receptor and transcriptional intermediary factor 2 protein-protein interactions. Assay Drug Dev Technol (2014) 0.77
Controversies on individualized prostate cancer care: gaps in current practice. Ther Adv Urol (2013) 0.76
Fisetin Enhances Chemotherapeutic Effect of Cabazitaxel against Human Prostate Cancer Cells. Mol Cancer Ther (2016) 0.75
Molecular imaging of urogenital diseases. Semin Nucl Med (2014) 0.75
Prognostic Significance and Functional Role of CEP57 in Prostate Cancer. Transl Oncol (2015) 0.75
Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles. Oncotarget (2016) 0.75
Emerging perspectives in prostate cancer: Insights from the 4th Asia Pacific Prostate Cancer Conference. Prostate Int (2015) 0.75
Dose-dependent effects of small-molecule antagonists on the genomic landscape of androgen receptor binding. BMC Genomics (2012) 0.75
Reconfiguring the AR-TIF2 Protein-Protein Interaction HCS Assay in Prostate Cancer Cells and Characterizing the Hits from a LOPAC Screen. Assay Drug Dev Technol (2016) 0.75
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst (2000) 133.74
Cancer statistics, 2010. CA Cancer J Clin (2010) 103.28
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science (2005) 39.06
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med (2004) 32.09
Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med (2010) 29.75
Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med (2011) 27.58
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med (2009) 24.75
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med (2004) 23.44
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet (2010) 19.74
Molecular determinants of resistance to antiandrogen therapy. Nat Med (2003) 18.90
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol (2008) 18.54
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol (2010) 17.13
Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther (2001) 14.78
Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res (2008) 14.37
Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science (2009) 13.87
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol (2008) 10.91
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet (2010) 10.79
Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer (2010) 10.61
Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res (2006) 9.87
Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol (2010) 9.86
Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol (1999) 9.22
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol (2008) 7.89
Autoantibody signatures in prostate cancer. N Engl J Med (2005) 7.56
Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell (2011) 7.32
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol (1996) 7.02
Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol (2004) 6.95
AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell (2011) 6.74
Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol (2009) 6.68
Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med (1995) 6.26
Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol (2010) 6.04
Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol (2010) 5.86
Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol (2006) 5.72
Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res (2005) 5.04
Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group. Lancet (2000) 5.03
Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene (2007) 4.81
Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res (2009) 4.68
Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol (2010) 4.64
Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer Cell (2011) 4.43
Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol (2004) 4.25
Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer (2008) 4.15
Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol (1999) 4.12
Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer (2009) 4.12
Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol (2012) 3.73
Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer. J Med Chem (1995) 3.72
Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer (2004) 3.32
Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol (2009) 3.24
Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase). J Steroid Biochem Mol Biol (1994) 3.19
A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer (2007) 3.15
Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. Lancet Oncol (2009) 3.13
Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene (2005) 3.13
Mechanisms underlying the development of androgen-independent prostate cancer. Clin Cancer Res (2006) 3.12
Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol (2009) 2.88
Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer (2008) 2.86
Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br J Cancer (2003) 2.43
Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res (2010) 2.42
Structural basis for androgen receptor interdomain and coactivator interactions suggests a transition in nuclear receptor activation function dominance. Mol Cell (2004) 2.38
Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin. J Clin Oncol (2008) 2.35
Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation. Proc Natl Acad Sci U S A (2007) 2.34
Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res (2009) 2.32
Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res (2009) 2.30
Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol (2010) 2.28
HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res (2000) 2.25
Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies. J Clin Oncol (2011) 2.14
BRAF targeted therapy changes the treatment paradigm in melanoma. Nat Rev Clin Oncol (2011) 2.10
The 16,17-double bond is needed for irreversible inhibition of human cytochrome p45017alpha by abiraterone (17-(3-pyridyl)androsta-5, 16-dien-3beta-ol) and related steroidal inhibitors. J Med Chem (1998) 2.08
Castration-dependent pharmacokinetics of docetaxel in patients with prostate cancer. J Clin Oncol (2010) 2.07
Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. Cancer Res (2003) 2.07
A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer. Ann Oncol (2007) 2.03
The androgen receptor negatively regulates the expression of c-Met: implications for a novel mechanism of prostate cancer progression. Cancer Res (2007) 1.99
Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells. Mol Endocrinol (1997) 1.90
A phase II clinical trial of sorafenib in androgen-independent prostate cancer. Clin Cancer Res (2008) 1.87
Targeting CYP17: established and novel approaches in prostate cancer. Curr Opin Pharmacol (2008) 1.85
The association between measures of progression and survival in castrate-metastatic prostate cancer. Clin Cancer Res (2007) 1.83
Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model. J Med Chem (2005) 1.80
A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Ann Oncol (2008) 1.80
Small molecule inhibitors targeting the "achilles' heel" of androgen receptor activity. Cancer Res (2011) 1.77
Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. J Urol (2002) 1.77
Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. J Clin Oncol (2010) 1.76
Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases. Clin Cancer Res (2007) 1.74
Androgen receptor mutations in prostate cancer. Cancer Res (2000) 1.74
Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426). Cancer (2008) 1.73
Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic. CA Cancer J Clin (2011) 1.68
Envisioning the future of early anticancer drug development. Nat Rev Cancer (2010) 1.67
Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. J Clin Oncol (2010) 1.65
Functional characterization of mutant androgen receptors from androgen-independent prostate cancer. Clin Cancer Res (1997) 1.62
Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer. Am J Med (1995) 1.60
Interaction of IGF signaling and the androgen receptor in prostate cancer progression. J Cell Biochem (2006) 1.59
Weekly docetaxel and prednisolone versus prednisolone alone in androgen-independent prostate cancer: a randomized phase II study. Eur Urol (2007) 1.57
A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin Cancer Res (2008) 1.56
Predictors of mortality after prostate-specific antigen failure. Int J Radiat Oncol Biol Phys (2006) 1.50
Imatinib mesylate and zoledronic acid in androgen-independent prostate cancer. Urology (2004) 1.48
Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug. Cancer Res (1993) 1.42
Drug development in oncology: classical cytotoxics and molecularly targeted agents. Br J Clin Pharmacol (2006) 1.40
Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy. Ann Oncol (2009) 1.40
Low doses of oral dexamethasone for hormone-refractory prostate carcinoma. Cancer (2000) 1.38
Sipuleucel-T. Nat Rev Drug Discov (2010) 1.37
Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer. Clin Cancer Res (2010) 1.37
An open-label, multicenter, phase I/II study of single-agent AT-101 in men with castrate-resistant prostate cancer. Clin Cancer Res (2009) 1.36
Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med (2011) 27.58
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med (2009) 24.75
Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med (2012) 20.79
Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med (2012) 15.69
Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med (2014) 11.05
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol (2008) 10.91
Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol (2009) 6.68
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol (2012) 6.49
Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol (2010) 6.42
Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol (2010) 5.86
Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol (2009) 5.45
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N Engl J Med (2015) 5.39
Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res (2009) 4.68
Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol (2010) 4.64
First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J Clin Oncol (2011) 4.53
Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Curr Opin Pharmacol (2008) 3.41
Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. Lancet Oncol (2013) 3.38
Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. Lancet Oncol (2009) 3.21
Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer. BJU Int (2005) 3.06
Steroid hormone receptors in prostate cancer: a hard habit to break? Cancer Cell (2009) 2.85
Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100. Cancer Res (2012) 2.81
The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol (2013) 2.72
Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven. Cancer Res (2009) 2.62
Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clin Cancer Res (2007) 2.61
Serum androgens as prognostic biomarkers in castration-resistant prostate cancer: results from an analysis of a randomized phase III trial. J Clin Oncol (2013) 2.57
Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J Clin Oncol (2010) 2.47
Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer. J Clin Endocrinol Metab (2011) 2.32
Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study. Lancet Oncol (2012) 2.31
Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies. J Clin Oncol (2011) 2.14
Targeting the PI3K/AKT pathway for the treatment of prostate cancer. Clin Cancer Res (2009) 2.04
New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway. Clin Cancer Res (2011) 2.01
Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio. Cancer (2014) 1.93
Targeting CYP17: established and novel approaches in prostate cancer. Curr Opin Pharmacol (2008) 1.85
Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic. CA Cancer J Clin (2011) 1.68
Envisioning the future of early anticancer drug development. Nat Rev Cancer (2010) 1.67
Translating scientific advancement into clinical benefit for castration-resistant prostate cancer patients. Clin Cancer Res (2011) 1.64
Targeting the insulin-like growth factor signaling pathway: figitumumab and other novel anticancer strategies. Expert Opin Investig Drugs (2011) 1.53
Abiraterone acetate is well tolerated without concomitant use of corticosteroids. J Clin Oncol (2010) 1.51
Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma. Cancer Chemother Pharmacol (2009) 1.50
Psychosocial effects of cancer cachexia: a systematic literature search and qualitative analysis. J Pain Symptom Manage (2012) 1.50
CYP17 inhibition as a hormonal strategy for prostate cancer. Nat Clin Pract Urol (2008) 1.49
A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors. Clin Cancer Res (2008) 1.47
Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development. Cancer J (2009) 1.46
A phase I study of the combination of intravenous reovirus type 3 Dearing and gemcitabine in patients with advanced cancer. Clin Cancer Res (2010) 1.42
Cancer cachexia: a systematic literature review of items and domains associated with involuntary weight loss in cancer. Crit Rev Oncol Hematol (2011) 1.41
Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer. Invest New Drugs (2012) 1.38
Utilizing circulating tumor cells: challenges and pitfalls. Curr Opin Genet Dev (2010) 1.34
Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective. Eur J Cancer (2010) 1.32
Development of therapeutic combinations targeting major cancer signaling pathways. J Clin Oncol (2013) 1.30
Multi-purpose utility of circulating plasma DNA testing in patients with advanced cancers. PLoS One (2012) 1.27
External quality assurance of circulating tumor cell enumeration using the CellSearch(®) system: a feasibility study. Cytometry B Clin Cytom (2010) 1.24
Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development? Drug Discov Today (2009) 1.24
Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignancies. Clin Cancer Res (2011) 1.21
Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors. J Hematol Oncol (2014) 1.20
A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors. Cancer Chemother Pharmacol (2013) 1.19
Novel, gross chromosomal alterations involving PTEN cooperate with allelic loss in prostate cancer. Mod Pathol (2012) 1.19
Metastatic castration-resistant prostate cancer (CRPC): preclinical and clinical evidence for the sequential use of novel therapeutics. Cancer Metastasis Rev (2014) 1.11
Evolving classification systems for cancer cachexia: ready for clinical practice? Support Care Cancer (2010) 1.10
Tumor survivin is downregulated by the antisense oligonucleotide LY2181308: a proof-of-concept, first-in-human dose study. Clin Cancer Res (2010) 1.05
Circulating Tumor Cells Count and Morphological Features in Breast, Colorectal and Prostate Cancer. PLoS One (2013) 1.04
Targeting the DNA damage response in oncology: past, present and future perspectives. Curr Opin Oncol (2012) 1.04
Unbiased and automated identification of a circulating tumour cell definition that associates with overall survival. PLoS One (2011) 1.03
The emerging role of poly(ADP-Ribose) polymerase inhibitors in cancer treatment. Curr Drug Targets (2011) 1.03
The association of PI3 kinase signaling and chemoresistance in advanced ovarian cancer. Mol Cancer Ther (2012) 1.01
Appraising iniparib, the PARP inhibitor that never was--what must we learn? Nat Rev Clin Oncol (2013) 1.01
Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study. Clin Cancer Res (2013) 0.99
The CT flare response of metastatic bone disease in prostate cancer. Acta Radiol (2011) 0.99
Targeting the HGF/c-Met axis: state of play. Mol Cancer Ther (2010) 0.98
Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy. Eur J Cancer (2013) 0.98
Therapy monitoring of skeletal metastases with whole-body diffusion MRI. J Magn Reson Imaging (2014) 0.97
Targeting insulin-like growth factor signaling: rational combination strategies. Mol Cancer Ther (2010) 0.97
Sarcomatoid carcinoma of the prostate: ERG fluorescence in-situ hybridization confirms epithelial origin. Histopathology (2014) 0.97
The promise of circulating tumor cell analysis in cancer management. Genome Biol (2014) 0.95
A phase I study of quisinostat (JNJ-26481585), an oral hydroxamate histone deacetylase inhibitor with evidence of target modulation and antitumor activity, in patients with advanced solid tumors. Clin Cancer Res (2013) 0.95
Predictive biomarkers for targeting insulin-like growth factor-I (IGF-I) receptor. Mol Cancer Ther (2009) 0.95
Belinostat: clinical applications in solid tumors and lymphoma. Expert Opin Investig Drugs (2011) 0.94
FGF receptor inhibitors: role in cancer therapy. Curr Oncol Rep (2012) 0.94
Prostate cancer: PSA as an intermediate end point in clinical trials. Nat Rev Urol (2009) 0.92
HGF/c-MET targeted therapeutics: novel strategies for cancer medicine. Curr Drug Targets (2011) 0.91
Baseline circulating tumor cell counts significantly enhance a prognostic score for patients participating in phase I oncology trials. Clin Cancer Res (2011) 0.91
Utilizing pharmacokinetics/pharmacodynamics modeling to simultaneously examine free CCL2, total CCL2 and carlumab (CNTO 888) concentration time data. J Clin Pharmacol (2013) 0.90
Putting the brakes on continued androgen receptor signaling in castration-resistant prostate cancer. Mol Cell Endocrinol (2011) 0.89
Molecular pathology and prostate cancer therapeutics: from biology to bedside. J Pathol (2014) 0.88
Studies of TMPRSS2-ERG gene fusions in diagnostic trans-rectal prostate biopsies. Clin Cancer Res (2010) 0.88
A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma. Cancer Chemother Pharmacol (2006) 0.87
PARP inhibitors: mechanism of action and their potential role in the prevention and treatment of cancer. Drugs (2012) 0.87
Early oncology clinical trial design in the era of molecular-targeted agents. Future Oncol (2010) 0.87
Reporting the capture efficiency of a filter-based microdevice: a CTC is not a CTC unless it is CD45 negative--letter. Clin Cancer Res (2011) 0.87
Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I/II study. Invest New Drugs (2014) 0.86
Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration-resistant prostate cancer. Prostate (2011) 0.85
Therapeutic options for advanced prostate cancer: 2011 update. Curr Urol Rep (2012) 0.84
A phase I dose-escalation study of the immunocytokine EMD 521873 (Selectikine) in patients with advanced solid tumours. Eur J Cancer (2012) 0.84
Randomized Phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer. Future Oncol (2014) 0.82